Hua Ling Medicine: Dapagliflozin Approved for Listing in Hong Kong Special Administrative Region of China

On the morning of March 3rd, Hualing Pharmaceutics announced on the Hong Kong Stock Exchange that their globally pioneering new drug Glucokinase Activator Deglycine has been approved for listing by the Drug Office of the Department of Health of the Hong Kong Special Administrative Region of China. It is used to treat adult type 2 diabetes.